

P1486

Abstract (poster session)

Tigecycline and comparators activity in vitro against multidrug-resistant Gram-negative bacteria in Latin America collected in 2007-2010

M. Renteria*, M. Hackel, S. Bouchillon, D. Hoban, B. Johnson, R. Badal, S. Hawser, M. Dowzicky (Schaumburg, US; Epalinges, CH; Colleville, US)

Background: Reduced treatment options for multi-drug resistant (MDR) gram negative bacteria are a major cause of mortality for patients with nosocomial infections. The global Tigecycline Evaluation Surveillance Trial (TEST) evaluated the activity of tigecycline and comparators against MDR *Acinetobacter baumannii*, *Enterobacter aerogenes* and *E. cloacae* from Latin America during 2007-2010. Methods: A total of 1,852 clinical isolates of *A. baumannii*, *E. aerogenes* and *E. cloacae* were collected from multiple infection sources in ten countries in Latin America during 2007-2010. MICs were performed at each site using prepared broth microdilution panels following CLSI guidelines. MICs were interpreted according to CLSI/FDA guidelines. MDR isolates were defined as those resistant to three or more antimicrobial drug classes. Results: MIC₅₀ and MIC₉₀ in mg/L, as well as % susceptible (%S) are shown in the following table for tigecycline and selected comparators: na: no defined breakpoint. Conclusions: In vitro susceptibility data shows tigecycline and minocycline with the lowest MIC₉₀ values against MDR *A. baumannii*, with an MIC₉₀ of 2 mg/L and 8 mg/L for tigecycline and minocycline, respectively. Against *Enterobacter* spp., tigecycline and meropenem exhibited the lowest MIC₉₀s of 2 mg/L and <=4 mg/L, respectively. These findings suggest that tigecycline may be a potential therapeutic option in the treatment of MDR gram-negative bacteria in patients from Latin America.

Drug	<i>A. baumannii</i> (n=1,149)			<i>E. aerogenes</i> (n=179)			<i>E. cloacae</i> (n=903)		
	MIC ₅₀	MIC ₉₀	%S	MIC ₅₀	MIC ₉₀	%S	MIC ₅₀	MIC ₉₀	%S
Tigecycline	0.5	2	na	0.5	2	91.6	1	2	92.8
Cefepime	> 32	> 32	7.4	4	> 32	58.7	4	> 32	66.7
Levofloxacin	> 8	> 8	3.6	2	> 8	50.8	1	> 8	59.8
Meropenem	> 16	> 16	14.2	0.12	4	84.9	0.12	1	91.6
Minocycline	1	8	86.7	4	> 16	51.4	8	> 16	34.3
Pip-Tazo	> 128	> 128	1.7	32	> 128	40.8	32	> 128	44.2